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 Since 1971, when US president Richard Nixon declared a “war against cancer”, an 
estimated $200 billion has been spend on research and drug development for cancer. Globally, 
the cancer incidence and the mortality rates have declined over the past decade, owing to 
progress made in healthcare and biological research. In order to study the biological properties 
of cancers and to enable novel drug discovery, in-vitro model systems are used and the most 
common amongst these are cancer cell lines. These are primary-tumor derived cells that are 
propagated in the lab, and are used to study both the biological and pharmacological aspects 
of cancer. The use of cell lines in research, in the field of cancer diagnostics, has resulted in a 
number of drugs that are now available in the market to combat cancers.  
 Since the isolation of the first cancer cell line, HeLa, in 1951, a number of cell lines are 
available for various types of cancers and these have been around for decades now. Cell lines 
in culture not only lose the properties of their cells of origin gradually, they also acquire 
mutations over each passage that causes the lines to behave very differently as compared to 
primary tumors. Additionally, there is competition among populations of cells in culture and 
it is widely believed that cell lines that are presently available are largely clonal populations of 
those cells that grow faster and survive better as compared to others. This results in loss of 
heterogeneity that is characteristic of in-vivo cancers.  
 In order to quantitatively assess the fidelity of these cell lines, we use a modified 
version of the network biology platform CellNet to construct tumor type specific gene 
regulatory networks for twelve common primary cancers and train random forest classifiers. 
Using expression data from 917 cell lines as the query and comparing their GRNs (Gene 
Regulatory Networks) against the tumor type specific classifiers, the probability scores for each 
	 iii	
of these cell lines to resemble primary tumors are calculated. Those cell lines that show a high 
classification score to their tumor type of origin are considered ideal in vitro models for that 
cancer. The GRN status and network influence scores were also calculated for cell lines and 
using these statistics and CellNet predictions, in-vitro models for cancer research are 
suggested.  
 Additionally, we propose the use of Cancer CellNet as a clinical diagnostic platform 
to resolve the tumor identity in unknown cases and demonstrate its ability to obtain this 
information using tumor samples where the cells of origin of cancer remain unknown. 
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Chapter 1 – Introduction 
1.1 Motivation for the project 
The American Cancer Society estimated a total of 14.5 million people living with a 
history of cancer in the United States of America on January 1 2014 and by 2017, a cumulative 
total of 1.7 billion new cases (1930-2017) are expected to be diagnosed globally. Around 35% 
of this number are expected to succumb to this deadly disease by 2016, which translates to 
approximately 1650 deaths a day1,2.  This makes cancer the second deadliest disease, next only 
to cardiovascular disease. The sites where cancer is predicted to occur in these cases, and the 
projected percentage of deaths is depicted in Figure 1.1.   
Figure 1.1 – Gender-wise estimates for leading sites of new cancer cases (2016)1 
Even though the number of people suffering from cancer seems to be an appalling 
number, the number of cancer deaths has reduced by 23% from the projected numbers, due 
to advances in diagnosis and treatment, as well as significant improvements in lifestyle, thus 
avoiding almost 1.7 million cancer deaths. A trend line showing the year-wise mortality rates 
per cancer-type for both males and females, from 1930 – 2012 is shown in Figure 1.2, and it 
shows the decline in the number of deaths since 19901.   
&!
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Figure 1.2 – Gender-wise cancer mortality rates by site from 1930-2012 in the USA3 
Advances made in biomedical research has contributed directly in this decline in 
mortality rates due to cancer, not only by providing therapeutic drugs that help to cure or 
contain cancer but also by improving diagnostic tools that aid in early identification of the 
disease, thus improving the disease prognosis. The National Cancer Institute is one of the 
biggest funding bodies in America supporting investigator-driven cancer research and in 2017, 
an estimated $5.21billion in total has been allocated for this purpose. 
Human-cancer derived cell lines are the most popular cancer models used in research 
and they are used not only for advancing our understanding of the disease but also for 
developing novel therapeutics and improving efficacy of treatment4. For decades, cell lines lay 
the foundation for advancement in cancer biology and many models were established for 
studying various cancers. However, there was always criticism in using cell lines as cancer 
models as there are modifications that are introduced in cells isolated from tumors to enable 
their propagation indefinitely in culture. Thus, a lot of the cell lines do not actually recapitulate
the features of tumors in vivo. For example, glioblastoma-derived cell lines form a ball of cells 
as opposed to a spider-web like infiltration as observed in human brains and thus, do not make 
accurate models for the primary tumor5. However, there are other cell lines models that have 
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proven instrumental in the development of drugs. An example of this would be the MCF-7 
breast cancer cell line that has been used in clinical trials for many drugs like Faslodex, which 
have been established as successful drugs in the market6. Cell lines are also useful to study rare 
cancers, where primary samples cannot be obtained readily due to the complex location of the 
tumor or its rarity among the population7.  
 There are other concerns regarding the use of cell lines as tumor analogs, like the 
contamination of cell lines with cells from other cell lines (cross-contamination). Back in the 
1970s, researchers discovered through cytogenetic studies that cell lines used as models for 
various cancers were all derived from the HeLa cell line, which was a cervical cancer cell line8 
and not the tumors they intended them to represent. Immortalizing primary cells obtained 
from humans in order to convert them into a cell line has also been shown to modify the 
characteristics of the cells, deviating from the exact tumor profile.  
 With advances in genomic technologies, many primary tumor samples have been 
sequenced and genomic information is now available, the largest of which is the Cancer 
Genome Atlas (TCGA)9. Back to back publications in 2010 provide a comprehensive analysis 
of mutations and copy number variations (CNVs) in human cancers10,11. There was a debate 
for many years concerning the merit of sequencing cancer cell lines, but a stark reduction in 
the cost of genomics resulted in the publication of the Cancer Cell Line Encyclopedia (CCLE), 
a comprehensive study encompassing expression profiles of ~1000 cancer-derived cell lines12.  
 A pilot study in 2013 by Domcke et al, compared genetic and expression profiles of 
the CCLE ovarian cancer cell lines, with profiles of primary tumors. The authors found that 
cell line models for ovarian cancer were those that showed least similarity to the in vivo tumor 
profile13. As part of their study, they also ranked ovarian cancer cell lines by their resemblance 
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to the ovarian tumors, so that ideal in vitro ovarian cancer models can be used in research.  
 In this thesis, I aim to assess the fidelity of vitro models for some of the most widely 
occurring cancers like breast cancer, prostate cancer and leukemia, among others. However, 
as opposed to comparing lines and tumors by global expression data, I use Gene Regulatory 
Network (GRNs)14 as a basis for comparison. These GRNs are compared with those obtained 
from cell lines to classify them on the basis of their resemblance to those primary tumors 
whose GRN profile they most resemble. In addition to assessing cell line models for multiple 
cancers, this study will also explore possible molecular contributors differentiate between 
tumors and cell lines. The information obtained from analyzing thousands of primary tumor 
samples also paves way to explore the cellular origins of CUP (Cancers of Unknown 
Primary)15 and Merkel Cell Carcinoma16, which remains unknown.    
1.2 Organization of the thesis  
 Chapter 1 highlights the motivation for this study. Chapter 2 provides the relevant 
literature review of the field and defines important terms that are used throughout this thesis. 
Chapter 3 contains the detailed workings of the computational protocol with the syntax 
expanded and the tools that were employed to run the code effectively. Chapter 4 describes 
the results obtained at the end of our computational analysis of various cell lines and Chapter 
5 contains a comprehensive list of all the references used in this thesis. The entire Cancer 
CellNet code is provided as part of the Appendix.   
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Chapter 2 – Background 
2.1 In vitro cancer models 
 Cancer is a collection of many diseases into one due to diverse cells of origin and 
plethora of molecular mechanisms underlying disease, not to mention the very strong 
environmental contribution to the triggering of certain types of cancers17. The genetic and 
environmental influence in determining the susceptibility of a person to get a positive cancer 
diagnosis makes cancer a complex disease, as opposed to being a metabolic or a genetic 
disorder. This molecular heterogeneity in the origin and propagation of cancer is what makes 
cancer one of the deadliest diseases in history and one of the hardest to cure.  
 In order to design molecules that can treat cancerous cells specifically, a thorough 
understanding of the cellular and molecular aspects of the disease needs to be achieved. The 
advances made in the field of cancer pathophysiology rely heavily on the availability of a variety 
of in-vitro model systems, each of which models a particular aspect of this diverse disease. A 
few such models are cancer cell lines18, tumor primary cultures, primary tumors19, xenografts 
and genetically modified mice20. The choice of cancer model depends on the aim of each 
particular study as each model system mentioned above is accompanied by its own set of 
advantages and limitations. Cancer models also provide a low cost screening platform for 
novel cancer therapeutic drugs.  
 The need for improved accuracy and relevance of tumor models has resulted in an 
increase in complexity of in vitro tumor models, where they progressed from just simple cell 
proliferation and cytotoxicity screens to those that incorporate metastasis, matrix remodeling 
and angiogenesis. This was made possible due to advances in the fields of tissue engineering, 
biomaterials, microfluidics and tumor biology21. There is also scope for the development of 
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patient-specific in vitro cancer models22 in order to personalize the treatment regimen in 
certain rare or complex cases.   
 In vitro tumor models that currently exist in the field are designed to recapitulate not 
only the biological profile of cancers with respect to cell composition, but also the physical 
aspects like ECM structure, migration of cells, invasion, extravasation and angiogenesis. These 
are popularly referred to as 3-D tumor models and are used to study drug delivery mechanisms 
as well as tumor microenvironment complexity studies. The source of cancer cells for these 
models can be either cell lines or cells from the primary tumor itself. The latter source provides 
various advantages such as understanding the heterogeneity in tissue composition of the 
cancer, comparison of results across various biological samples and more importantly, 
recapitulating the in vivo tumor characteristics.  
 Advances made in diverse fields like microfluidics, fluid dynamics, biomaterials and 
polymers have led to the development of in vitro cancer models with increased complexity. 
However, currently available cancer models are classified broadly as the following: Transwell-
based, Spheroid-based, Tumor-microvessel or hybrid model systems and these are explained 
in Katt et al 201621 in detail.  
 Despite these more advanced models, cell lines are by far the most widely used cancer 
models due to their low cost, ease of isolation and manipulation.  
2.2 Cancer cell lines as tumor models 
 HeLa was the first cancer-derived cancer cell line to be established. It was derived 
from Henrietta Lacks, a cervical cancer patient at Johns Hopkins Hospital in 1951 by George 
Gay23. This cell line had infinite proliferative potential and was widely distributed across the 
world. Since the successful establishment of this cell line, similar culturing techniques were 
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used to establish cell lines from thousands of primary tumors over a period of two decades. 
These cell lines paved way to significantly advance the frontiers of cancer research, clinical 
diagnosis and development of therapeutic drugs. The major advantage cancer cell lines provide 
researchers is that they provide theoretically infinite supply of a relatively homogenous supply 
of cancer cells, to be experimented upon. A more detailed review of cancer cell lines and their 
uses in the field of drug development is provided by Ferriera et al24. The major disadvantages 
provided by cancer cell lines as an experimental model for tumors is listed below:  
i. Genomic instability due to repeated culturing 
ii. Dominance of specific clones over the other cell types that were originally a part of 
the tumor sample  
iii. Cross contamination with other fast growing cell lines like HeLa 
iv. Differences in environment of cells as compared to in vivo tumors  
v. Loss of cellular heterogeneity in culture 
vi. Bacterial and mycoplasma contamination 
vii. Change in gene expression pathways due to absence of ECM signals present in tumor 
 There are over 3000 established cancer cell lines, isolated from multiple tissues and 
species. Characterization and re-authentication of these cell line models becomes crucial due 
to the following reasons: First is the high probability of cross contamination between cell lines 
due to their explosive proliferative potential25,26 and second is the absence of advanced 
molecular techniques during the time of their initial isolation that could have resulted in an 
erroneous characterization of cell lines4,13. Another major factor is the passage number of 
these cell lines in culture as mutations tend to accumulate in cells that have been repeatedly 
cultured, thus deviating from the molecular profile of the parent tumor.  
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 An example to illustrate the importance of accurate characterization of cell lines is the 
article published in 1999 that re-designated the cell line SW626 to be of colon origin as 
opposed to ovarian cancer which it was perceived to be since 197427. Groups establishing cell 
lines are required to provide multiple lines of evidence to confirm the tumor type and also the 
cell-type of origin for the cell line28, but such stringency was not possible during the early 
1970s which was when a lot of the presently used cell lines were established. Hence, there is 
an active effort by the scientific community to redefine established cancer cell line models with 
modern molecular techniques29, to re-instate the validity of these models as accurate 
representations of tumors for research. The various features that need to be characterized 
while establishing a new cell line are discussed in detail here30.   
 As mentioned in section 1.1, Domcke et al initiated the efforts in sifting through all 
available cell line models available for ovarian cancers with an aim to identify the most accurate 
in vitro model for this cancer type. Although they did selective screening with parameters like 
CNVs and mutations in specific genes to compare tumors and cell lines, their results indicated 
the level of disparity in the popularity of cell line models and the extent of their resemblance 
to their parent tumor. Studies aiming to understand tumor characteristics or pre-clinical trial 
studies with cell lines need to ensure thorough characterization of the cell line prior to use as 
a tumor analog in the laboratory and this project provides one such metric to perform this 
comparison, in the form of GRN reconstruction and comparison between cells and tumors.  
2.3 Gene Regulatory Networks (GRNs) 
 Cells are surrounded by extracellular matrix (ECM) that contains a myriad of signals 
which cells interpret and respond to accordingly. These signals vary depending on the 
environment and the physiological state of the organism and the responses are also 
-!
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correspondingly different and they also vary between different cell types. This signal 
perception and response is achieved due to certain regulatory mechanisms that are 
programmed within the cell and these are executed by various proteins. One such regulatory 
mechanism is gene regulation and this is orchestrated by a number of proteins within the cell. 
Gene regulation can include both transcriptional and post-translational regulation, where the 
former is governed predominantly by transcription factors (TFs) and the latter by RNA 
binding proteins.  
GRNs are mostly discussed in the context of transcriptional regulation. GRNs are 
essentially circuits that describe physical and/or regulatory interactions between transcription 
factors and their target genes14. GRNs include both physical interactions such as that of a TF 
with the DNA binding element or regulatory (logical) interactions which are more indirect in 
nature, and are inferred due to genetic experiments.  
Figure 2.1 shows a schematic depicting the major elements that are a part of a 
transcriptional Gene Regulatory Network.  
 
Figure 2.1 – Elements of a transcriptional GRN  
Since transcriptional GRNs are essentially like circuits, they contain two elements: 
nodes and edges, where nodes are TFs and the target genes while edges are the regulatory 
relationship between them, which can be physical or logical. For a given cell in a given 
condition and a given environment, the GRN can vary anywhere from a few TFs and its 
corresponding targets to a complex mesh of multiple TFs, whose targets can be other TFs and 
thus, leading to a big network map, like the one shown in Figure 2.231.  
%.!
Figure 2.2 – GRN of interactions between C.Elegans TFs and metabolic target genes 
Unlike gene expression profiles obtained from microarray platforms, GRNs provide a 
more comprehensive idea about the transcriptional state of a cell at a given time, as they not 
only provide information about TF expression, but also about their target gene regulation32.  
2.4 CellNet  
CellNet is a network biology platform that was designed with the aim of assessing cell 
populations obtained through directed differentiation of induced pluripotent cells (iPSCs) or 
direct conversion of one cell type to another. It also suggests hypotheses aimed at improving 
these conversion protocols33. It uses a modified version of the CLR algorithm (refer section 
2.5) to reconstruct cell-type specific GRNs. Once the classifiers are built, it quantitates the 
classification score of a given query sample into a particular tumor type using a Random Forest 
Classifier (refer section 2.6).  
The pipeline takes as input, expression data obtained from public sources and using 
constructed cell/tissue type specific GRNs from hundreds of input sample of that particular 
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tissue as a basis for comparison, provides three outputs:  
i. A classification probability score which indicates the extent to which the input has a 
profile indistinguishable in its expression profile as compared to a particular 
cell/tissue (classification score).  
ii. The extent to which a cell/tissue specific GRN is established (GRN status) 
iii. The list of TFs that are a part of the cell/tissue GRN, scored according to how 
dysregulated they are and by the dysregulation of their targets (Network Influence 
Score or NIS).  
 CellNet was initially designed to take as input, microarray expression data from mouse 
and human samples, and assess the extent of cell fate engineering from iPSCs. However, 
recently this pipeline has been modified to take in RNA-sequencing data as input, as RNA-
sequencing is replacing microarrays as one of the cheapest genomic tools for whole 
transcriptome assessment and provides a more comprehensive view of the genetic state of a 
cell34. Until now, cell/tissue GRNs were constructed by CellNet using normal cells obtained 
from various tissue types as input and in this project, we modify the pipeline to construct 
tumor-type specific GRNs (ttGRNs) by providing primary tumor data as input (Cancer 
CellNet).  
2.5 CLR algorithm  
 The Context Likelihood of Relatedness (CLR) algorithm is an unsupervised network 
inference method 35 and is an extension of the relevance inferences algorithm for the 
identification of transcriptional regulatory interactions36,37.  The relevance method scored 
interactions between two genes on the basis of similarity in their expression levels and the 
threshold they set for extent of similarity determines the size of the network, as a lower 
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threshold will capture more interactions, some of which may be false positive and others which 
may be novel. CLR is similar to the relevance network but it adds another layer of complexity, 
by comparing the expression similarity of a particular interacting pair with the extent of 
similarity of other background interactor pair. Thus, it puts each pair in context with others, 
and eliminates all those interactions that are weak or non-specific, thus eliminating a huge 
percentage of the false positives that are captured by the relevance network. CLR can achieve 
a high-precision regulatory interaction network with as few as 60 expression datasets as input, 
and this becomes a lower threshold for training CellNet’s pipeline.  
2.6 Random Forest classifiers  
 Random Forests are an ensemble learning method that operates by constructing 
multiple decision trees and providing as output, either the mean prediction of regression of 
each individual tree or a classification score that is a mode of the individual classes38. In GRN 
reconstruction, the decision trees start with one gene that is either randomly selected or is 
selected based on the importance of a gene to that particular cell type.  
 CellNet employs random forest classifiers to construct the ttGRN based classifiers 
which will serve as the basis for comparison with the query datasets. For each platform, a 
single RF classifier was trained on a particular tumor type. Every gene that is specific to the 
ttGRN is used as a predictor variable in the construction of these trees, and the output of each 
tree is binary. GRN status of a sample can sometimes be weighed by the importance of a gene 
to the Random Forest classifier, as opposed to the mean expression profile in the training 




Chapter 3 – Materials & Protocol 
 In this chapter, the computational tools used for analyzing the 917 cancer cell lines 
from the Cancer Cell Line Encyclopedia is described in brief. The cancer CellNet pseudo code 
is presented, in detail,  
The complete Cancer CellNet code is available in the Appendix.   
3.1 Using Amazon Web Services (AWS) 
 Storage of the expression data files for all the samples to be queried and executing 
Cancer CellNet was achieved using Amazon Web Services (AWS), which is a comprehensive 
cloud computing platform. Among the growing selection of services made available for users 
by AWS, this project utilized EC2 and S3. EC2 or Elastic Compute Cloud allows customers 
to run applications on virtual interfaces called instances, which can be configured by the user 
and are theoretically unlimited in number. S3 or Simply Storage Service is a scalable, high 
speed, low cost storage service intended to backup or archive user data. The various steps 
involved in using this system is described below in detail.  
3.1.1 Launching an EC2 instance  
 An instance is the virtual server in Amazon’s Elastic Compute Cloud (EC2), which is 
used to run applications and computations on the AWS infrastructure. The configuration of 
the virtual interface used to perform the desired function can be assembled from a variety of 
instance types, each with different memory, storage capacity and computing power to suit the 
needs of the consumer.  
 Instances are created from Amazon Machine Images or AMI’s, which are essentially 
templates that are configured with an Operating System and software in accordance with the 
needs of the user. A variety of in-build AMIs are made available for use but users can also 
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create their own AMIs, by customizing the virtual machine or VM to determine the working 
environment. For this project, the AMI called CellNet_RNA-seq_Pub (AMI ID - ami-
1ad4430d) was launched with c3.8x large instance type and launch-wizard-1 security group.  
 Once an instance is launched and is running successfully, the terminal application is 
used to securely connect to the virtual machine by using the following command:  
ssh –i aws_private_key_path ec2-user@instance_public_dns  
 
The private key pair is locally downloaded and saved in your working directory and is detected 
when one attempts to connect to an instance. Once the connection is successful and you enter 
the virtual machine, all computations are performed in the cloud  
3.1.2 Data handling in S3  
 Amazon S3 is an object storage device, which is different as compared to a block 
storage or a file storage device. The S3 cloud service provides the user with services similar to 
the one used by Amazon websites, which includes the facility to upload, download and store 
any object in its cloud database, up to a 5GB in size. The S3 cloud is divided into logical units 
of storage called buckets which are used for storing objects, consisting of data plus the 
metadata that is used to describe the data. 
3.1.3 AWS Command Line Interface (CLI)  
 The CLI is a tool that helps manage AWS services by automating through scripts and 
help controlling the AWS through the command line. It includes a set of file commands that 
make transfers to and from S3 highly efficient and can be achieved in parallel. The commands 
that are used as a part of the Cancer CellNet code is described in detail below: 
To view the contents of a bucket/folder in S3:  
$ aws s3 ls s3://mybucket 
$ aws s3 ls s3://mybucket/folder_path 
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To copy contents of a local folder to a folder in S3 or vice-versa: 
$ aws s3 cp myfolder s3://mybucket/myfolder –-recursive 
  
upload: myfolder/file1.txt to s3://mybucket/myfolder/file1.txt 
upload: myfolder/file2.txt to s3://mybucket/myfolder/file2.txt 
  
$ aws s3 cp s3://mybucket/myfolder myfolder --recursive 
  
download: s3://mybucket/myfolder/file1.txt to myfolder/file1.txt  
download: s3://mybucket/myfolder/file2.txt to myfolder/file2.txt 
 
 The --recursive tag is used to ensure that all the contents within a folder are copied 
into the destination folder.  
To sync the contents of a local folder to a folder in S3 or vice-versa: 
$ aws s3 sync myfolder s3://mybucket/myfolder --exclude *.tmp 
 
upload: myfolder/new.txt to s3://mybucket/myfolder/new.txt 
 
 The --exclude tag, as the name suggests, will exclude particular files and in this case, 
all files with the .tmp extension, and syncs everything else in the parent folder to the 
destination folder. 
3.2 Cancer CellNet protocol 
3.2.1 Cancer CellNet construction 
 Cancer CellNet is a derivative of CellNet and is designed to analyze the GRN status 
of cancer cell lines and tumors, by comparing them to the training data containing gene 
expression profiles of primary tumors. TtGRNs (tumor type specific gene regulatory 
networks) is defined as the steady state expression profile of a particular tumor type and we 
%*!
measure the established ttGRNs for 12 types of primary tumor datasets, which serve as 
training data for Cancer CellNet. Based on the classifiers constructed as a result of training the 
program, expression profiles of query datasets, which in this case are cancer cell lines obtained 
from a particular tissue, can be used as inputs, to obtain the probability that the ttGRNs in the 
cell lines are indistinguishable from each tumor type in the training data set. For more 
information   
All of the data used in this study is obtained from Affymetrix U133 Plus 2.0 microarray 
platform, and this was kept consistent across both training and query data sets in order to 
make the expression data comparable and to eliminate differences between platforms. The 
number of samples used to build the classifiers is tabulated below in Table 3.1. The raw 
expression files associated with these samples were curated from GEO (Gene Expression 
Omnibus) by our collaborator, Edroaldo Lummertz da Rocha and stored in S3.  
Table 3.1 – Cancer CellNet training data sample set
3.2.2 Outline of the procedure  
The overall procedure for Cancer CellNet, including the acquiring of data and 
preprocessing, training Cancer CellNet and running it on the query data set is depicted in 
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Figure 3.1. The procedure consists of two phases, Training Cancer CellNet where the tumor 
type classifiers are constructed based on the primary tumor data shown above is fed into the 
pipeline, and Querying Cancer CellNet, where the query data comprising of CCLE cell lines 
is fed as input to provide classification scores with respect to each tumor type classifier. The 
entire procedure is split into 10 subsections, each of which is explained in detail in the 
following sections: 
Figure 3.1 – Outline of the Cancer CellNet procedure
3.3 Training Cancer CellNet  
Cancer CellNet (CCN) is an adaptation of the CellNet pipeline for cancer data. In 
order to train CCN, the raw .CEL files which contain expression data from the primary tumor 
samples listed in Table 3.1 were used. The detailed procedure for in this process is described 
below and the numbers in the titles correspond to the steps depicted in the above figure:  
I.! Obtain expression files for training CCN (by Edroaldo) 
Manual curation of primary tumor data was done, by browsing through GEO manually 
for datasets corresponding to the twelve tumor types listed above, and care was taken to ensure 
the platform was consistent across the files. The compressed .zip files uploaded onto the S3 
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server into the designated folder and unzipped to get .CEL.gz files. This process was 
performed for all of the samples shown in Table 3.1 and will serve as input to the CCN 
pipeline, in order to train the classifiers.   
II.! Creating the training sample table  
Using a spreadsheet editor, a csv (comma-separated value) file was created describing 
the annotation information for the training data samples. In this project, the training data 
sample table is called “stTrain.csv”. The sample table is loaded into S3, so it can be called into 
the instance, during CellNet training. A subset of the training data sample table is shown in 
Table 3.2 below.  
Table 3.2 – Subset of the training sample table 
Legend: 
exp_id – The GEO experimental ID which identifies the parent dataset  
sample_id – The specific GEO accession number for each sample that is a part of exp_id 
sample_name – The name of the tumor sample assigned by the authors 
cfname – The name of the raw expression data file obtained after unzipping the .zip file  
description1 – The broad definition of the tumor type representing each sample  
description2 – The germ layer from which the tissue originates from, during development 
If sample_name is not specified by the authors of the dataset, it is initialized as the 
sample_id. The cfname serves as the link for the sample table to the raw data files stored in 
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S3, and helps in fetching the data during the execution of the program. Description1 will be 
the annotation for the classifiers to be built and hence, need to be consistent in annotation 
between all samples isolated from a particular tissue, within the sample table. Description2 
helps differentiate between germ layers of origin and this becomes useful when the 
transcription factors that are part of the GRN are analyzed. TFs can play differing roles in 
various tissues and also during different stages of development and it becomes essential to 
have information about the germ layer of origin for the tumor tissue type, in order to get a 
better idea about the TFs that are dysregulated in these different tumor types.   
III. Pre-processing training data 
 Pre-processing involves fetching the raw expression files, unpacking them, getting the 
raw data and normalizing them. In order to perform all these functions across the training data 
set, EC2 was used. After logging in to the AWS console, the CellNet-RNASEQ AMI was 
launched with c3.8x large instance type. Once the instance has initialized, terminal was 
launched and secure shelled into the running instance as described above. The steps involved 
in pre-processing are described in detail in the following points.  
a) Screen is launched using the command “screen” typed into the terminal. This allows the 
processes to be detached and reattached, and is useful when the connection to the instance 
breaks or to toggle between multiple processes that are run in parallel in the same instance. 
b) Create a new folder within the ephemeral drives, that are a part of the instance opened. 
This becomes necessary due to the large size of raw data that is about to be processed 
during training.  
sudo mkdir /media/ephemeral0/data 










d) R is launched within the same folder and the necessary packages and source codes are 






e) The sample table created is loaded from S3, into the instance using the AWS CLI described 
above. That is initialized to the variable “stTrain”, and this notation will be used 
consistently to denote the training sample table. The row names of the sample table need 
to be initialized to the sample id. This step is crucial in order to be able to link the 
annotation table and the expression matrix that will be generated at the end of the 
preprocessing step.  
samptab <- read.csv(“sample table training.csv”) 
row.names(samptab) <- samptab$sample_id 
 
f) Individual functions are written to take as input, the cfname of the sample, and fetch the 
file from the S3 location specified, unzip them and introduce a new element in the sample 
table stripping the “.gz” from the name of the file, under the column titled “file_name”. 
g) Since the number of files that are present in the training data table is huge, all files cannot 
be unzipped and processed at the same time as it may crash the instance, and so, subsets 
of files need to be pulled up at a time. In order to group the training data into groups, their 
experimental id was used. All unique experimental ids were loaded into a vector.   
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sids <- unique(as.vector(samptab$exp_id)) 
 
h) All rows of sampTab containing samples belonging to a particular exp_id are grouped into 
a separate sample table, stTest, that will be used to obtain a normalized expression matrix: 
stTest<-sampTab[which(sampTab$description1==sid),] 
write.csv(stTest, file="stTrain_expn.csv") 
stTrain <- expr_readSampTab("stTrain_expn.csv") 
expTest <- Norm_cleanPropRaw(stTrain, "hgu133plus2") 
 
 where sid is an element in the vector sids. This process iterates through all values of 
sids to obtain expTrain for all samples in stTrain. Each expTest contains all the genes 
corresponding to the probes on the microarray platform, listed along the rows and each 
column represents a particular primary tumor sample. This normalization is a crucial step 
in preprocessing and all the expTest tables are given unique names and stored in S3 for 
other analyses.  
i) Once the expression scores are obtained, the next step is to get a merged expression file 
and this can be achieved by combining all of the individual expTest tables as follows.   
expTrain <- cbind(expTrain, expTest) 
 
 This command is executed at the end of every expTest generation step, prior to the 
start of the next iteration, so at the end of the loop, expTrain is a large expression matrix 
containing all the samples along the columns and all the genes along the rows. This R object 
is saved in S3.  
IV. GRN construction 
 This step constructs tumor type specific Gene Regulatory Networks (ttGRNs), using 
the following function. 
grnProp <- cn_make_grn(stAll, expAll, species = "Hs",  
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tfs = hsTFs, dLevel = "description1", dLevelGK = 
"description2") 
 The arguments of cn_make_grn take as input, the sample table and the normalized 
expression matrix, created in the steps above. They also specify the species that the samples 
belong to, as the set of TFs differ across species. dLevel specifies the various tumor types we 
want ttGRNs to be constructed for and dLevelGK helps in distinguishing germ layer 
differences between tissue types, as the same TF may play different roles in different tissues 
and knowing the germ layer of origin for a particular tissue helps in constructing the GRN. 
The grnProp obtained as a result of GRN construction is also saved in S3 for future use, so 
the process does not have to be repeated.   
 The stringency parameters for constructing GRNs was adjusted that each ttGRN 
contained a minimum of 12 TFs that are associated with it. This becomes important to obtain  
V. Train and assess Cancer CellNet 
 In this step, the classifiers formed as a result of the GRN construction are assessed. 
The way this is done is to split the training data into two parts (in this case, it was split into 
equal parts), and using one part to train Cancer CellNet and the other part serves as validation 
data. The results are stored in a list, that can be used to construct heat maps and PR curves, 
assessing the classifiers.  
classifierPerformance <- cn_splitMakeAssess(stTrain,  
expTrain, grnProp) 
 
 classifierPerformance is a large list that contains three parameters: PR curves, 
classifiers and the classRes, which is a large matrix containing the probability scores for the 
validation data. Good classifiers should result in high precision for high recall values. They are 
described in more detail in Chapter 4. The classification heatmap should result in all tumor 
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samples derived from a particular tissue classifying correctly as that particular tumor type. The 
code used to obtain these graphs is described in section 3.5.  
 Once the quality of the classifiers is assessed and deemed satisfactory, a large R object 
is created that contains all the information contained in the classifiers like normalized 
expression values (expTrain), the sample table for the training data (stTrain), the ttGRNs etc. 
This will be the object used while querying data in the steps below. In order to create this 
object, the following lines of code are used.  
cnProc <- cn_make_processor(expTrain, stTrain, grnProp)  
 
 This is the most important object that is obtained as a result of training CellNet and 
this is also saved in S3 for use in the following steps.  
3.4 Querying Cancer CellNet using Cancer Cell lines  
 In order to assess the fidelity of cancer cell lines that are in use in research, the CCLE 
database was used and the following steps were performed to feed the expression data from 
each of these cell lines into Cancer CellNet that is trained with primary tumor data.  
VI. Obtained expression files for cancer cell lines 
 The compressed file containing the expression data from all 917 cancer cell lines was 
obtained, uploaded into S3 and unzipped to obtain all the raw .CEL.gz files in the required 
folder.  
VII. Creating the query sample table 
 As described in part II, a csv file was created using a spreadsheet editor, a sample table 
was created, describing the annotation information for all the cell lines in the CCLE database, 
similar to Table 3.2 but with an extra column containing the names of the cell lines (cell_name) 
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was added. This sample table was named “stQuery.csv” and was uploaded into S3 so as to be
called into the instance, while running Cancer CellNet.   
Table 3.3 – Cancer CellNet query data sample set – CCLE cancer cell lines 
The cancer cell lines in CCLE were derived from 26 major tissue types and they are 
listed across two columns in Table 3.3. The ones highlighted in green are those tumor types 
that are a part of the training data set. 
VIII.! Pre-processing query data 
Similar to section III above, the raw data for the cancer cell lines is extracted and the 
expression data is normalized. Since the aim of the project is to assess cancer cell lines based 
on their fidelity with respect to primary tumors, it makes sense to query all cell lines belonging 
to a particular tissue type together, as opposed to querying all cell lines together. The latter will 
result in a very populated heatmap that becomes hard to interpret.  
The following steps are performed to obtain expQuery, which is a matrix containing 
normalized expression data for all cell lines belonging to a particular tumor type and is repeated 
for all distinct tumor types listed in Table 3.3.  
a)! Launch screen by typing “screen” in the terminal. This enables us to log back in, when 
the instance pipe gets broken.  
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b) Create a folder within the ephemeral drive as shown above and download the sample 
table and the cnProc from S3. The cnProc created at the end of training and the query 
sample table are downloaded into the working directory inside the instance. These are 
initialized to variables cnProc and sampTab respectively.  
source(“cellnetr_utils.R”) 
cnProc <- utils_loadObject(“cnProc.rda”) 
sampTab <- read.csv(“sample table query.csv”) 
row.names(sampTab) <- sampTab$sample_id 
 
c) Since we are grouping the cell lines as per their tissue of origin, the sids vector will be 
initialized as shown below, and not by experimental ID.  
sids <- unique(as.vector(sampTab$description1)) 
 
The following steps will be looped for every element in the vector “sids”. This way, all 
cell lines belonging to every tissue type gets extracted and their expression data analyzed. 
d) A subset of the query sample table is taken from sampTab, the raw files fetched from S3, 
unpacked, and the expression data normalized as described in step (h) in section 3.3. The 
individual expression matrices are combined into a large expression matrix, that contains 
genes along the rows and the cell lines along the columns. This normalized expression 
matrix is called “expQuery”.  
IX. Analyze query data  
 Once we have the expQuery, and the stQuery with rownames equal to the sample_id, 
and the cnProc obtained as a result of training CellNet, we are ready to query the data against 
the classifiers established by the training data set. The following command runs CellNet and 
compares the expression data of each sample against the training classifiers: 
tmpAns <- cn_apply(expQuery, stQuery, cnProc) 
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 The tmpAns is an R object of class cnRes and it can be obtained for each of the 26 
tissue types, and saved in S3 with the file name containing the tissue type it represents. This 
way, a particular subset out of all the tissue types can be chosen for further analysis. Using this 
result, the best cell line models for each type of tumor can be identified.  
3.5 Additional function definitions   
3.5.1 Creating classification heat maps 
 In order to create heat maps, the “pheatmap” function was used. As arguments for 
this function, the matrix that contains the classification probability scores for each specific 
tumor type, and color cues to specify the range of values were fed. The following code does 
this for one specific example:  
newHm <- function(cnRes){ 
classMat <- cnRes$classRes 
cools <- colorRampPalette(c("black", "green", "yellow"))(100) 
pheatmap(classMat, col = cools,  
         breaks = seq(from = 0, to = 1,length.out = 100),  
         border_color = bcol, cluster_rows = FALSE,  
         cluster_cols = TRUE, 
         fontsize = 5) 
} 
library(pheatmap) 
tmpAns <- utils_loadObject(“tmpAns_ovary.rda”) 
newHm(tmpAns)  
 
3.5.2 Calculating Network Influence Scores (NIS) 
 Network Influence Score indicates the extent of dysregulation of the transcriptional 
regulator and its target genes in the sample, weighted by the importance of that TF to that 
particular tumor type GRN. This can be used to prioritize hypotheses to explain the molecular 
differences between cell lines and tumors. It is defined using the following formula: 
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 where TR is a transcriptional regulator and n is the number of genes in the GRN for 
a particular tumor type (TT). Weight is the difference in expression with the mean expression 
of the gene in that tumor type, calculated in the classifiers. The weight of the TR and its targets 
is calculated by CellNet by their mean expression in the tumor type samples that are a part of 
the training dataset when searching for inappropriately silenced factors.  
 The code used to calculate NIS for each cell lines grouped per tumor type, takes as 
input the cnProc that is obtained as a result of training CCN and the cnRes obtained for that 
particular tumor type cell lines at the end of running Cancer CellNet. The syntax is as follows:  
tfScores <- cn_nis_mod(cnRes, cnProc, subnet, tumor-type) 
 
 where subnet refers to a subset that is taken for evaluation, like all “prostate” samples 
for example and tumor-type refers to the name of the classifier, whose ttGRN is being 
compared against, which in this case can be any one of the 12 tumor types used in training 
CellNet. The function cn_nis_mod calculates the NIS scores for all TFs that are a part of the 
ttGRN for that tumor type. The expanded code for cn_nis_mod can be found in github.  
 The variable “tfScores” contains the NIS for each of the TFs associated with the tumor 
type specific GRN. These values can be negative or positive depending on increase or decrease 
in the level of expression of the TF, as compared to the corresponding value in the tumor type 
classifier. In order to consider the fold change and not the direction, absolute values of NIS is 
obtained and TFs are arranged in decreasing order of this fold change for each cell line, with 
the most misregulated TF being on top. The frequency of occurrence of a particular TF among 
the top 10% in each cell line is calculated and tabulated, and this process is repeated for every 
tumor type analyzed.  
	 28	
3.5.3 Obtaining GRN status  
 GRN status is a measure of the extent of establishment of a specific ttGRN in the 
query set. This is defined as the weighted sum of the z scores of the genes in the GRN. The 
formula used to calculate raw GRN status is as follows:  




 where n is the number of genes in the GRN and gene weight is the proportional 
expression in the tumor type. The raw GRN status scores are normalized to the final GRN 
status that gets plotted, in order for a better score to indicate a better resemblance to the 
training data GRN.  




 where the denominator term represents the average raw GS of tumor type samples in 
the training data. This is plotted by providing the function with the cnProc used to construct 
the classifiers and the cnRes object obtained at the end of CellNet querying, and mentioning 
the tumor type to be compared against. The syntax is as follows:  
cn_barplot_grnSing(cnResQuery, cnProc, GRN_tumor_type, 
training_GRN , query) 
 
 where GRN_tumor_type is the tumor type specific GRN, to which the extent of 
establishment is measured in the query samples. training_GRN is the extent of the GRN 
establishment for cell_type_1, in the training dataset. This serves as a control relative to which 
the query samples are measured. query is a string containing the order of query samples to be 
displayed in the final plot.  
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3.5.4 Obtaining citations from Pubmed  
 In order to obtain the number of citations in Pubmed for each of the cancer cell lines 
in our study, published in the context of cancer, the search term included the terms “AND 
cancer” along with the name of each cell line, to limit the hits to only those publications that 
were in the context of this project. The following lines of code was used to automate this:  
tumor_type <- read.csv(“sample_table_tt.csv”) 
cell_lines <- as.data.frame(tumor_type$cell_line) 
for (i in 1:nrow(cell_lines)){ 
  cell_lines[i,2] <- as.character(paste(query_aml[i,1], "AND 
cancer*[tw]")) 
} 
query <- as.vector(query_aml[,2]) 
names(query) <- query_aml[,1] 
df <- PubMedTrend(query) 
 
 where the sample table for a particular tumor type, containing all the names of cell 
lines that are derived from that tumor is extracted and the term “AND cancer” is appended 
to the names. This is then fed to the function PubMedTrend that has been expanded in 
Github. The output of this function results in a data frame containing the number of hits for 
the search-term in Pubmed, listed year-wise. That dataframe can be written into a csv file and 
used for further analysis.   
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Chapter 4 - Results 
4.1 Training Cancer CellNet and assessing the classifiers 
  As described in section 3.3, the CellNet pipeline has to be trained with primary tumor 
data in order to construct the ttGRNs for all primary tumor types, in order to be able to classify 
cancer cell lines based on their classification scores obtained after passing them through CCN. 
Cancer CellNet was trained using data obtained from samples listed in Figure 3.1 (initial 
training of CCN performed by Kathleen diNapoli). The ttGRNs constructed at the end of this 
training was analyzed for checking the quality of training data using two tools:  
a. Classification heatmap 
  The classifier performance R object obtained at the end of training, as 
described in step V of the CellNet procedure, contains the classification scores for those 
samples that were a part of the primary tumor expression data set, that was used as query to 
assess the ttGRNs constructed at the end of CellNet training (Split and assess function 
described above). These classification scores are represented in the form of a heatmap as 
shown in Figure 4.1.  
 The rows represent the 12 primary tumor types that constitute the training data set 
and the columns are arranged in order of the annotated tumor type of that sample.  For 
example, the first 507 columns are samples that are annotated in the training sample table as 
being derived from AML, and hence, should show a perfect classification with AML as the 
ttGRNs for this tumor type was constructed using this data as input. And this logic applies 
for all of the tumor types that are a part of the training data set. If there are certain samples 
that do not classify to the right tumor type, that indicates a bad tumor dataset.  
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In order for the training to be successful, and the ttGRNs be considered valid 
representations of the actual tumor type, the heatmap should show little to no such 
misclassification, and those sample that classify correctly should also exhibit a classification 
score close to 1. This becomes crucial because if there is a significant portion of the training 
data that is either mis-annotated to be from a tumor type that is different to that it is annotated 
to be from, or if the expression data is not of good quality, it will affect the ttGRN construction 
for that tumor type. This may result in errors while using these parameters to query the cell 
line expression data, resulting in either false negatives or false positives.  
Figure 4.1 – Classification scores to test the quality of training data   
Analysis of Figure 4.1 shows good classification for samples derived from 
most tumor types, except kidney, melanoma and ovary. A significant number of kidney tumor 
samples show an overlap with liver, while melanoma and ovary are showing a non-specific 
classification with breast. However, with these few exceptions, most of the validation dataset 
classified in accordance with their tumor types of origin, with high probability scores. Overall, 
this training of CellNet is considered successful.   
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b.! Precision-Recall curves 
This analysis depicts both the sensitivity and precision of the classifiers to accurately 
classify a sample correctly into its tumor types. Precision and recall are defined using the 
following formulae:  
Precision!=!
 true positives






In words, precision translates to the ability of the system to detect true positives among 
all “perceived” positives and recall is detection of true positives from “actual” positives. These 
terms have an inverse correlation as the more precise it gets, the lesser its recall is going to be. 
The PR curves represent the relationship between precision and recall, and ideally, the 
precision should remain high for almost all values of recall.  
 
Figure 4.2 – Precision-Recall curves for CellNet generated tumor type classifiers  
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 PR curves were plotted for each of the tumor type classifiers and represented in Figure 
4.2. These were obtained from the classifier performance R object that is obtained at the end 
of step V in the CellNet pipeline (Refer Chapter 3). From the PR curves obtained at the end 
of training, all the tumor type classifiers show very high precision values with respect to high 
recall. Some tissues like ovary and prostate show lesser precision than others, but they are 
100% precise up until recall values of 0.9, which indicates a very good classifier.  
 Thus, training of Cancer CellNet using the primary tumor data was successful in 
establishing ttGRNs and was used for querying cell line expression datasets, described below.  
4.2 Querying cell lines from tissue types in the training dataset 
  The dataset used to train CellNet and build the classifiers is a compilation of 
expression data derived from primary tumor samples originating from 12 tissue types. Cell 
lines derived from these tumor types will thus serve as the first set of query datasets, in order 
to assess the validity of these cell lines as accurate models of the corresponding tumors.  
4.2.1 Acute Myeloid Leukemia (AML) cell lines 
 Acute Myeloid Leukemia or AML is a tumor of the hematopoietic and lymphoid tissue 
and is characterized by proliferative, abnormally differentiated or de-differentiated cells of the 
hematopoietic system infiltrating the bone marrow, blood and other tissues39. The genome of 
AML tumors show relatively lower mutation profiles as compared to other types of cancers40, 
with an average of 13 mutated genes41, according to the Cancer Genome Atlas Research 
Network.  
 A number of cell lines have been established from AML patients and the CCLE12 
profiles 26 such cell lines. Running the expression data obtained from these cell lines through 
CellNet resulted in classification of all cell lines as AML-derived, as shown in Figure 4.3. The 
'(!
figure shows all 26 cell lines along the x-axis and the heat map represents the probability of 
the query exhibiting GRN genes to an extent that is indistinguishable from the tumor type 
mentioned along the y-axis. The AML cell lines are ordered in increasing order of their 
probability scores for AML tumor type, the lowest scoring line being on the left.  
Figure 4.3 – Classification of AML cancer cell lines 
AML cell lines are derived from different cell types; for example, HL-60 is a pre-
myeloblast cell line whereas AML-193 is a monocyte derived42. Given this diversity, the 
robustness of the classification shows that the underlying GRNs are similar across all AML 
cell lines and they also serve as a true representation of primary AML tumors, since the 
probability of classification for all cell lines was higher than 50% and show almost no non-
specific classification with other tissue types. From this classification heatmap, it can be 
inferred that there are some cell lines which show minor probability of classifying to other 
tumor types, like the ovary. In order to better understand why this occurs, the tumor-type 
specific GRNs (ttGRNs) for each of the cell lines that can be extracted from the result of 
running Cancer CellNet (cnRes object), were analyzed (“tmpAns” – refer step IX of the
CellNet protocol in Chapter 3).  
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There were 71 component transcription factors (TFs) in the AML-specific-GRN that 
were identified as a result of training Cancer CellNet with AML primary tumor samples. The 
Network Influence Score (NIS) for each of these TFs was calculated across all 26 AML-
derived cell lines, as described in the methods section. The frequency of the most dysregulated 
TFs across all queried cell lines are tabulated in Table 4.1.  
 Table 4.1 – Frequency of maximally-misregulated ttGRN specific TFs across AML-cell lines 
ELF-1 is E-74 like ETS Transcription Factor 1 and it encodes a protein that is 
primarily expressed in lymphoid cells and is known to act as both activator and inhibitor of
gene expression43. Importantly, it plays a crucial role in the transcription of the TCR ! chain 
and expression of this protein is reduced in many hematological malignancies including AML. 
Expression level of ELF-1 was measured from 33 patients suffering from AML and it was 
observed that the protein was overexpressed in all of them, as compared to healthy controls. 
It is believed that the down-regulation of the TCR ! chain in AML leads to a feedback 
regulation in the expression of ELF-144. However, in all of the AML derived cell lines that 
show relatively poorer classification scores with the AML classifier, the ELF-1 expression is 
~2 fold lower than the mean expression level in the ttGRN.  
	 36	
NFIL3 (Nuclear Factor, Interleukin 3 Related) is a transcriptional regulator that binds DNA 
as a homodimer to ATF (Activation Transcription Factor) sites and represses transcription of 
those genes45. Thus, it acts as an inhibitor of the circadian rhythm genes PER1 and PER246 
but activates transcription of interleukin-3 promoter in T-cells. Since it restricts FOXO 
binding onto the promoter elements, this protein is referred to as a “survival factor”, and is 
up-regulated in AML “stem-cells”. In almost all of the cell line models, this gene’s expression 
levels are about one fold lower than primary tumor cells, but does not vary significantly 
between cell lines.  
 The third TF that is dysregulated in all of the AML cell lines is RNF10 (Ring Finger 
Protein 10), which has a ring finger motif that facilitates protein-protein interactions47. 
Interestingly, the specific function of this protein still remains unknown and its possible 
relationship with AML is unexplored.  
4.2.2 T-cell Acute Lymphoblastic Leukemia (T-ALL) cell lines 
 T-cell acute lymphoblastic leukemia is an immature, aggressive hematological tumor 
derived from early T-cell progenitors. Malignant hematopoietic cells expressing immature 
markers for the T-cell infiltrate the bone marrow resulting in increased white blood cell 
numbers and hematopoietic failure48. Based on gene expression signatures, there are multiple 
unique biological subgroups of T-ALL clinically, which result in different cellular 
phenotypes49. 
 T-ALL is considered a heterogeneous cancer type based on its immunological 
phenotype. Burger et al in 199950, analyzed the differences between all T-ALL derived cell 
lines used in research in a comprehensive manner. They performed southern blotting, 
immunophenotyping and TCR protein expression studies and their results showed a high 
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degree of heterogeneity among the 16 cell lines they analyzed. However, there was no 
comparison between the cell lines and primary tumors in this study.  
Figure 4.4 – Classification of T-ALL cancer cell lines
Fifteen T-ALL cell lines were characterized in the CCLE database, and analyzing the 
GRN-based tissue classification of these cell lines resulted in highly specific classification into 
the T-ALL tumor type, as shown in Figure 4.4. Thus, it can be concluded that although among 
T-ALL cell lines and in-vivo tumors, there exists phenotypic heterogeneity, the cell lines that 
are used to research this type of leukemia recapitulate the transcriptomic characteristics of the 
primary tumors with fidelity, few cell lines with higher similarity to the tumor profile than 
others.  
Among the cell lines, the one showing maximum classification with the T-ALL tumors 
was PF-382, with a score of 88% and it was isolated from a 6 year old female with a second 
relapse of the disease51. In order to understand the molecular players that are different in cell 
lines as compared to the primary tumors, the TFs that are a part of the ttGRN profile are 
analyzed and those that deviated from the tumor expression level in 50% or more of the cell 
lines are tabulated in Table 4.2 below.  
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Table 4.2 – Frequency of maximally-misregulated ttGRN specific TFs across T-ALL cell lines 
JUND codes for the JunD protein that is a functional component of the AP-1 
transcription factor complex and its major role in normal cells is to prevent p-53 dependent 
senescence and apoptosis52. It is a proto-oncogene and is commonly associated with diseases 
like Leukemia, especially adult T-cell leukemia53. There are no known reports linking the 
activity of this gene to be responsible in T-ALL till date. However, in a T-ALL cell line called 
CCRF-CEM, which was not a part of this study, p53 induced apoptosis was found to be 
enhanced54 and in the cell lines that are a part of our analysis, the expression levels of JUND 
appears to be down-regulated. If the trend continued across all T-ALL derived cell lines, this 
may result in increased incidence of apoptosis in cells during culture.  
TNFAIP3 is Tumor Necrosis Factor Alpha-induced protein 3 and it is a ubiquitin-
editing enzyme. This protein is actively involved in inflammatory and immune pathways in the 
body. This gene, along with TCF7 (T Cell Factor 7), which is also a part of Table 4.2, are 
responsible for the regulation of T-cell receptor expression on the surface of T-cells. Although 
T cell surface markers are aberrantly expressed in T-ALL disease manifestation, the down-
regulation of these genes in culture results in deviation from cell surface marker profile of in 
vivo cancer cells.  
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4.2.3 Central Nervous System (CNS) tumor derived cell lines
There are three major classes of brain tumors namely astrocytomas, 
oligodendrogliomas and meningiomas55. Table 4.3 shows the number of samples in both the 
training and the query dataset, derived from specific types of brain tumors. It can be seen that 
~62% of the training data comprises of glioblastoma tumors, which are the most commonly 
occurring subtype of glioma in humans. Glioblastomas are also referred to as “Grade 4 
Astrocytomas” and are the most malignant form of brain tumors derived from the supporting 
cells of the CNS, namely the glia56. Thus, it is also the most researched among other forms of 
gliomas and almost 70% of all CNS cancer derived cell lines originate from glioblastomas. 
In 2007, the World Health Organization (WHO) classified central nervous system 
tumors according to the microscopic similarities between putative cells of origin, 
predominantly done by Hematoxylin and Eosin (H&E) staining of tissue sections, and their 
presumed level of differentiation57. This eliminated the diversity between tumors derived from 
the same class of cells, for example, all astrocytic tumors were classified together irrespective 
of their diversity in clinically manifested phenotypes. However, the latest WHO classification, 
published in 201658, updates this classification and incorporates the various differences 
between tumor types and provides an updated synopsis of tumor classification of the CNS.  
 
Table 4.3 – Types of gliomas and composition of the training and query data sets 
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The CCLE database was compiled and published in 2012 and thus, used the 2007 
broad classification to group cancer cell lines. Therefore, when the 46 CNS derived cancer cell 
lines were run through the CellNet algorithm to obtain tumor type classification, the results 
showed no strong correlation to the brain tumor training dataset, as shown in Figure 4.5. The 
heatmap has been arranged in increasing order of probability of the queried cell lines to classify 
as brain, and it can be seen that a majority of cell lines do not classify as brain or any other 
tumor type in general. This can also be explained by the fact that the CNS-tumors originate in 
cell types that are completely different from one another in their morphology, function and 
hence, their inherent gene expression profiles. But, grouping them under the broad umbrella 
of CNS-derived tumors eliminates this diversity, and while averaging out the primary tumor 
profiles to get a consensus ttGRN, these differences may have gotten filtered out.  
Figure 4.5 – Classification of CNS tumor derived cell lines 
The maximum probability score for cell lines to classify as brain, obtained from Cancer 
CellNet is 0.448 and this shows only moderate specificity for these cell lines to primary CNS 
tumors. The low scoring cell lines are predominantly those that have a non-specific CNS 
tumor origin and are underrepresented in the brain tumor training dataset, as can be seen from 
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Table 4.3, although some glioblastoma cell lines are also present in this category. Overall, 
~25% of the CNS derived cell lines show a tendency to classify as brain. The extent of brain 
GRN status achieved by CNS tumor derived cell lines is depicted in Figure 4.6, to better 
emphasize this point.  
Figure 4.6 – Brain ttGRN status for CNS tumor derived cell lines 
Among the cell lines profiled, the ones that classify the most as brain tissue and show 
a GRN status that resembles closest to the primary brain tumors are SNU-626, KNS-42 and 
U-251 MG, with classification scores of 0.41, 0.40 and 0.34 respectively. Analyzing the 
heatmap classification (Figure 4.5) for these three cell lines shows that SNU-626 and KNS-42 
have non-specific classification with some probability, to other tissue types like breast and 
ovary, which is absent in U-251 MG. Thus, based on these results, the use of U-251MG as an 
in vitro model for CNS tumor studies is recommended. 
4.2.4 Kidney tumor derived cell lines 
Kidney tumors can be of various types like transitional cell carcinoma, sarcoma, 
Wilms tumor and the most common type of kidney tumor, which accounts for 85% of all 
diagnoses, Renal Cell Carcinoma (RCC). This cancer is usually treated with invasive surgery 
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to remove the tumor as it is resistant to chemotherapy and radiation59. RCC is characterized 
by highly vascular tumors, targeted therapies such as inhibitors of mammalian target of 
rapamycin (mTOR) and vascular endothelial growth factor (VEGF) pathways are used to 
treat metastatic renal carcinomas.  
Figure 4.7 – Classification of renal cancer cell lines 
CCLE contained 20 kidney cancer derived cell lines and 15 of those were from RCC 
and the tumor type of the other 5 were not specified in their original publications. Running 
their expression data through CellNet trained with primary tumor samples resulted in a heat 
map depicted in Figure 4.7. The cell lines in the heat map are arranged in increasing order of 
probability of being classified as a kidney derived cell line. 19 of these cell lines are rightly 
classified as kidney tissue-derived, except BFTC-909 which shows negligible probability with 
the kidney derived ttGRN classifiers.  
BFTC-909 cell line was derived from a grade III transitional cell carcinoma from the 
bladder of a 64-year old male. Since it is derived from the bladder but annotated as a renal cell 
line, the absence of renal tumor specific GRNs would have resulted in a poor classification 
score for this cell line to be indistinguishable from primary kidney cancer. The A-704 cell line
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shows highest resemblance to the kidney tissue classifier and there is no significant overlap 
with other tissue types and hence, can be considered to be the best model for renal cancers, 
among the cell lines profiled in this study.   
Table 4.4 – Frequency of occurrence of dysregulated kidney ttGRN specific TFs across cell lines 
In-depth analysis of the TFs that are dysregulated in the kidney cancer cell lines reveal
that the NOSTRIN gene is down-regulated in all 20 cancer cell lines. NOSTRIN stands for 
Nitric Oxide Synthase Trafficking and this protein is expressed in highly vascular tissues like 
lung, kidney, heart and placenta60. Its function involves binding to eNOS (endothelial Nitric 
Oxide synthase), the enzyme that synthesizes nitric oxide within the cell and attenuates its 
function61. Thus, it has a significant role in processes like neurotransmission, vascular 
homeostasis and inflammatory responses. Knockdown of this gene has been shown to deter 
glomerulus function in zebrafish62. In human renal cancers, the expression of this protein is 
found to be higher than that of normal cells. Nitric Oxide dependent eNOS signaling has been 
shown to promote cancer cell survival under hypoxic conditions in many tumors63 but since 
cell lines do not have the glomerulus architecture and are not cultured under hypoxic 
conditions, it is possible that the NOSTRIN gene is constitutively down-regulated in those 
clones that now make up these renal cell lines. All cancer cell lines in culture presently are 
believed to be clonal populations of fast-growing clones.  
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4.2.5 Ovarian cancer cell lines 
 Ovarian cancer victimizes more than 100,000 women globally, and is the most lethal 
gynecological malignancy in the United States64. Epithelial ovarian carcinomas are divided into 
4 subgroups: serous, endometroid, clear cell and mucinous among which serous carcinomas 
are the most prevalent and aggressive. A particular subtype, high grade serous ovarian 
carcinoma (HGSOC), is responsible for ~66% of ovarian cancer fatalities65 and is one of the 
most extensively studied ovarian cancers. Due to the high frequency of occurrence of the 
serous subtype, primary tumor databases like TCGA66 are skewed with respect of number of 
studies of ovarian cancer subtypes like HGSOC and this point becomes an important one to 
note as one goes about analyzing the cell lines that are a part of this study.  
 Domcke et al13, in 2013, performed a bioinformatics-based comparison of gene 
expression and mutational profiles of 47 ovarian cancer cell lines that are widely used in 
research, with that of primary ovarian tumor samples, obtained from the CCLE and the TCGA 
respectively. Using information on mutation frequency, copy number variations obtained from 
mRNA expression data, the study derived and assigned a 'suitability score' (refer Methods) for 
cell lines that best represent serous carcinomas obtained from patients, and ranked their cell 
lines with respect to this score. Their suitability score (S) was a combination of Pearson’s 
correlation scores of cell lines with the average expression of tumors, factored with 
presence/absence of mutations in certain key genes, and hyper-mutated cell lines were also 
penalized. They concluded that cell lines most commonly used as in-vitro models do not 
resemble the parent tumors.  
 Here, we studied the properties of 44 cell lines that are a part of CCLE, and compared 
them with our extensively compiled primary tumor training data set. As can be seen from 
Figure 4.8, the cell lines are grouped in order of increasing probability of classifying into an 
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ovarian cancer-derived cell line. The cell lines corresponding to the highest probability 
measures also show reduced non-specific classification, as compared to those with low 
probability scores. JHOM-2B, the cell line that shows the least classification score with ovary 
but a reasonably high score with colon, had a significantly decreased expression of Pax8, a TF 
that is found in almost 90% of ovarian cancers67 and expressed at basal levels in all other 
ovarian cancer cell lines. Another ovarian cancer oncogene, YAP168, showed reduced 
expression exclusively in this cell line, as compared to others and this would have led to 
reduced classification as an ovarian cancer.  
Figure 4.8 – Classification of ovarian cancer cell lines 
Upon comparing the top 10 cell lines that most resemble ovarian cancer as a result of 
this study with the Domcke et al study, it is observed that there is 80% overlap between the 
top cell lines picked out by these studies. The two exceptions are KURAMOCHI and TYKnu. 
The cell line KURAMOCHI, which ranked highest in the 2013 study was excluded from our 
query dataset for Cancer CellNet, as its expression data was generated by the Affymetrix U133 
array, which was not the platform our training data is generated from. Surprisingly, TYKnu, 
which appears in their list is featured very low in the cell line ranking score generated from 
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Cancer CellNet. It only demonstrates an 18% probability to resemble the training dataset.  
The suitability score for all the cell lines obtained from their study and Cancer CellNet 
classification scores are compared in Figure 4.9. As can be seen, all of the cell lines our pipeline 
predicts to be good ovarian cancer models also exhibit a high suitability score. However, unlike 
the limited scope for resolution between the cell line models in the 2013 study, our analysis is 
able to provide a clear distinction between all the cell lines, as can be seen by their wide range 
of x-values in the graph shown below. Almost 50% of the Domcke et al high scoring cell lines 
performed poorly when their GRNs were compared with those of primary tumors.  
Figure 4.9 – Ovarian cancer cell line fidelity measurement comparison across two studies  
The TFs that are deviating from the primary tumor expression profile were analyzed, 
in order to determine the molecular mechanisms in which tumor cells in culture differed from 
their in vivo counterparts. Surprisingly, only 3 TFs were found to significantly vary consistently 
across all cell lines, with respect to the tumor profiles and these were WT1, MEIS1 and 
SOX17. WT1 is Wilms’ Tumor protein 1, an essential protein in the development of the 
urogenital system in humans69 and as the name suggests, the absence or inactivation of this 
(+!
protein leads to the formation of Wilms’ tumor. It is present in almost 95% of all primary 
serous ovarian carcinomas70,71, but strangely enough, it is consistently at-least two-fold down-
regulated in almost all the ovarian cancer cell lines. However, the top 5 cancer cell lines models 
predicted by Cancer CellNet showed close to basal levels of expression for this protein.  
4.2.6 Breast cancer cell lines 
Breast cancer is the second most widely occurring malignancy in world population, 
and the most researched cancer in the United States, where $600 million was spent in the year 
2016 alone. Due to significant progress made in this front the disease prognosis after an early 
diagnosis is very good72 leading to an overall increase in life expectancy of breast cancer 
survivors (Figure 1.2). Breast cancer can be sporadic or familial, where the former is an 
occurrence due to the environment of the individual while the latter is genetically 
transmitted73. Traditionally, breast cancer has been grouped into subtypes based on the 
presence of hormone receptors (estrogen and progesterone receptors) on cells, pathology or 
grade of the cancer74. However, with advances made in molecular and gene expression 
profiling, this classification is being refined to better indicate prognosis and pathogenicity.   
Table 4.5 – Origins of the most commonly used breast cancer cell lines75 
The first breast cancer cell line was established in 1958 and named BT-20. The most 
commonly used breast cancer cell line in research is MCF-7 as it is ideal for studying cancers 
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with hormone receptors as it expresses the estrogen receptor and hence, serves as a perfect 
model to study hormonal response. This is the most cited breast cancer cell line and was 
derived from pleural effusions in 1978. Most of the commonly used breast cell lines are derived 
from pleural effusions or aspirates and hence, are derived from tumor metastases and not the 
primary tumor itself. A list of the most cited breast cancer cell lines with their source is 
tabulated in Table 4.5.   
Figure 4.10 – Classification of breast cancer cell lines
Analyzing the expression data from the 57 breast cell lines through Cancer CellNet
resulted in low- to mid-range probability scores for classification into breast, as shown in 
Figure 4.10. The cell line depicting maximum likelihood to the breast cancer classifier is 
HCC2157 with a score of 0.43, and this cell line has very few citations on PubMed. A few of 
these cell lines show almost zero probability for classifying into a breast derived cell line and 
this could be due to the fact that most of these cell lines were not derived from the primary 
tumor tissue, but further analysis is required before the causality for poor classification can be 
determined. MCF-7 has been used extensively in clinical research and is the most cited cancer 
cell line across all tumor types, even though its classification score was only ~0.25. This line 
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was especially useful for the development of breast cancer drugs like Tamoxifen, as it proves
to be a reasonable drug target analog for primary breast tissue.  
It can be seen from the classification heatmap that many breast cancer cell lines show 
an overlap with ovarian classification to some degree. In some cases, the ovarian classification 
scores exceed that of breast, although as the classification into breast increases, the ovarian 
non-specificity goes down. In order to understand the extent of breast-tumor GRN 
establishment in these cell lines into breast, their GRN status was measured with respect to 
both ovary and breast and the results are depicted in Figure 4.11.  
 
Figure 4.11 – GRN status analysis for breast cancer cell lines 
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 The Breast panel in Figure 4.11 depicts the breast-tumor GRN status for all the breast 
cancer cell lines, and on the extremes are the GRN status for the primary tumor data sets. The 
ovary training dataset shows more than 60% similarity to the breast GRN even though only 
unique interactions are classified as a part of a ttGRN, during CLR based GRN construction 
during CellNet training. This implies that the inherent GRNs for these two tissues share a high 
degree of similarity even though identical players are not involved in their construction. 
However, while probing the ovarian GRN status (Ovary panel) for breast cancer cell lines, 
only a few cell lines like CAL-51 and Hs604.T rise above the breast primary tumor training 
threshold and show some degree of ovarian classification. These are the same cell lines that 
also show poor classification in the heatmap represented in Figure 4.10.  
4.2.7 Prostate cancer cell lines 
 The prostate gland is present as a part of the male reproductive system, and is located 
around the bladder, wrapped around the urethra as it exits the bladder. Cancer in the prostate 
is the most widely occurring cancer in men and is typically diagnosed in men over the age of 
fifty. This is one of the most extensively researched cancers and there are several known 
genetic and environmental causes that may trigger the onset of prostate cancer. The most 
common genetic factors are RNASEL, BRCA1, BRCA2 and HoxB1376.  
 The most widely used and cited cell line models for prostate cancer are DU-145, 
LNCaP and PC-3, and were considered the gold standard for cell lines of prostate cancer77. 
However, as can be seen from our classification metric depicted in Figure 4.12, they are not 
the best classified primary prostate tumor-like cell lines. DU-145 was derived in 197178, from 
a brain metastatic prostate tumor that showed hormone independence as the cells do not 
express Androgen Receptors (AR). PC-3 was isolated from a vertebral metastasis of the 
prostate tumor in the late 1970s79 and is similar to DU-145 with respect to hormone 
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intolerance. The third cell line, LNCaP was also isolated from a secondary metastatic site, this 
time the lymph node80, but this cell line shows AR expression and hence, is responsive to 
hormonal treatments. Since primary prostate tumors show expression of ARs, it is interesting 
to note that LNCaP resembles primary tumors better than the other two gold standard cell 
lines.  
  The three most cited cell lines used in prostate cancer, were isolated from metastatic 
tumors and hence, are by nature, more aggressive and lose some of the characteristics of the 
parent tumor. Even though they may serve as good models to test novel prostate cancer drugs, 
it becomes imperative to have a good cell line model to represent the primary tumor, and 
currently, all cell lines derived from prostate cancer, are from metastatic sites and there is a 
need to isolate cells from the primary tumor site, immortalize them and maintain them in 
culture. Studies with these cell lines will help prevent remission in the parent site as well, in 
cases where the prostate cancer is not completely surgically excised.  
 The two cell lines that show maximum similarity to primary prostate tumors are VCaP 
and MDA PCa 2b. Both these cell lines were isolated from vertebral metastatic sites but they 
have unique distinguishing features that places them closest to the primary prostate cancer 
cells. VCaP cells exhibit a unique gene rearrangement in serine 2–ETS regulated gene 
(TMPRSS2-ERG)81, which is a transmembrane protease that plays an important role in early 
prostate cancer invasion and metastasis. This rearrangement results in the creation of an 
androgen responsive oncoprotein and this cell line is one of the very few cell lines that contains 
this feature. MDA PCa 2b is also unique in the fact that it was isolated from an African 
American patient and this becomes important because of the fact that prostate cancer is most 
common among men of African American descent82, and this incidence dominance may have 
affected the skewing of the primary tumor dataset as well. In cases like this, where there is a 
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known predisposition for members of a certain section of the population for certain forms of 
cancer, drug development needs to be focused on developing targeted therapies and the choice 
of the right cell line becomes crucial in that process. 
Figure 4.12 – Classification of prostate cancer cell lines 
Among the 8 cell lines profiled in this study, 5 of them show minor classification into 
breast or ovary or both, and as prostate cancer is a disease that occurs in males, the overlap 
with female organs like breast and ovary was surprising. However, delving into the genetic 
mutations that are present in prostate revealed that the BRCA1/2 genes83, which are causative 
mutations in both breast and ovarian cancers, is also predominantly mutated in prostate 
cancer. Thus, the non-specific classification into breast/ovary that we observe in our query 
may be a result of these gene networks, that play a role in all three cancers.  
4.2.8 Conclusions from this section 
The classification heat maps for individual tumor types described above, provide an 
understanding into the relative levels of likelihood for a tumor derived cell line to resemble 
the in-vivo tumor with respect to its GRN profile. Overall, the number of cell lines derived 
from a particular tumor type that resemble the parent tumor are a relatively small percentage 
of the total number of cell lines derived from the same tumor. This is depicted in Figure 4.13, 
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where the cell lines derived from the tumor types described above are plotted along the x-axis 
on the basis of their classification score. Almost 70% of cell lines plotted show a 50% or lower 
classification score, with respect to their corresponding in-vivo tumor counterparts. Some of 
these cell lines with low scores may have specific properties that make them attractive models 
for certain studies, for ex- MCF-7, although is a low scoring breast line, expresses the hormone 
receptors and thus is a useful model in drug screening studies. However, the characteristics of 
the cell line used to study the properties of the tumor biology itself or those used as precursors 
to clinical trials need to resemble their in-vivo counterparts to a reasonable extent and 
obtaining their probability score using GRN profile can serve as one such screening tool to 
prune cell lines that are unfit models for cancer. This can also serve as an important parameter 
to record while isolating/establishing a new cell line from novel or rare cancer types.  
 Also shown in Figure 4.13 is the relationship between the classification score obtained 
from Cancer CellNet with Normalized citation index. This term is defined as follows:  
Normalized citations index=
Number of citations for cell line
Number of citations for tumor type
 
The ideal relationship between these two parameters would be a direct correlation but the 
figure shows an almost inverse correlation, with a few exceptions. This implies that in majority 
of cases, the most heavily cited and hence most researched cell line for a particular tumor type 
has low resemblance with that primary tumor. 13 out of 19 cell lines that have a normalized 
citation index above 0.1 fall below the 50% classification score threshold. Similar results were 
observed by Domcke et al when they did this analysis for ovarian cell lines, where popular cell 
line models do not recapitulate tumor characteristics. These results together reiterate the need 
for a thorough re-characterization of cell line models for primary tumors prior to use for 
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academic or medical research, using high throughput genomics and proteomics techniques 
available now and this platform can be one such tool to aid in this process.  
 
Figure 4.13 – Correlation between tumor classification scores and normalized publication index 
4.3 Querying cell lines from tumors not in the training dataset 
Tumors exhibit heterogeneity in a cellular, physiological and genetic level84 and it is 
this property that makes it a very hard disease to cure completely. Metastatic cancers result in 
formation of tumors in secondary sites and these masses exhibit properties that are sometimes 
an amalgamation of both primary and secondary tissue sites.  
The CCLE database contains cell lines derived from tumor types that are not a part of 
our training data set. In order to test the similarity of cell lines from different tumors to the 
primary tumors that are part of our training data, the ttGRNs derived from these cell lines 
were queried and the results for three such data sets are described below.  
4.3.1 Cancer cell lines from hematopoietic lineages  
Blood cancers can be of three major types: Leukemia, Lymphoma and Myeloma85. 
Leukemia is the cancer of the bone marrow and results in the production of excess of
abnormal white blood cells into the bloodstream86. Lymphoma, as the name suggests, is the 
cancer of the lymphatic system, which is responsible for removal of excess fluid from the 
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body. Cancer in this system results in the production of abnormal lymphocytes, which are also 
important in fighting off infection87. Both these diseases decrease the immunity in the patient. 
Myeloma is the cancer of the plasma cells, which are white cells that produce antibodies to 
fight disease, and thus antibody production is impaired in patients suffering from myeloma88. 
In the CCLE database, there were 109 cell lines that were derived from hematopoietic 
or lymphoid tissue but were not annotated as TALL or AML, which were the two types of 
blood cancers that were a part of the training data set. Thus, these 109 cell lines were grouped 
under the broad umbrella of blood-derived cancer cell lines and queried against our Cancer 
CellNet derived classifiers. The resulting heat map, depicted in Figure 4.14, showed some 
specific classifications into TALL and/or AML but a majority of the cell lines showed no 
specific alignment with any one tissue type, with a reasonably high probability.  
37% of them aligned with TALL, 18% with AML, 0.01% with breast and ovary each 
and the remaining ~45% did not show any specific tissue classification, (using a 0.2 
classification threshold) as shown in Figure 4.15.  
Figure 4.14 – Classification of hematopoietic cancer cell lines 
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Figure 4.15 – Tissue specificity of blood-derived cancer cell lines  !
Analysis of the cell lines that actually aligned with either TALL or AML led to some 
interesting correlations. Burkitt Lymphoma is a form of non-Hodgkin’s lymphoma that 
originates in the B cells and it is the fastest growing human tumor that leads to high fatality89. 
In our query data set, there were 10 cell lines derived from Burkitt Lymphoma and all of them 
classified as TALL when run through Cancer CellNet, with a probability of 28%. Among other 
types of cancers that also classified as TALL are Hodgkin lymphoma, chronic lymphocytic 
leukemia and B cell lymphoma. Cell lines that classified as AML were predominantly the cell 
lines derived from Chronic Myeloid Leukemia or CML, and the two diseases share more 
commonalities in gene expression profiles than either of them with T-ALL, although they 
result in different manifestations of the disease and clinical symptoms. 
4.3.2 Endometrial cancer derived cell lines  
Endometrial cancer arises in the endometrial lining of the uterus and is common in 
post-menopausal women above the age of 50. If diagnosed early, this disease has a good 
prognosis rate and is treated through surgical removal of the uterus (abdominal hysterectomy) 
but still remains the third leading cause of death in cancers that affect women90. Some of the 
main risk factors for the occurrence of this cancer are obesity, estrogen exposure and genetic 
predisposition. The estrogen dependence becomes an important point of consideration as 
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selective estrogen receptor modulators (SERMs), like Tamoxifen, are commonly used 
treatments for breast cancer, and thus making the incidence of endometrial cancer higher 
among patients who have been treated with SERMs for breast cancer91. In many cases, 
endometriosis is also found to be a precursor for ovarian cancer in women.  
There are two main types of endometrial cancer, Type-I which occurs in 80% of cases 
and is endometroid and hyper-estrogenic in origin. Type-II on the other hand, is not 
endometroid in origin and does not show association with hyper-estrogenic factors like obesity 
and is usually highly dangerous with great metastatic and recurrence potential91.  
There are 25 cell lines that are of endometrial-tumor origin in the CCLE database, 
which have been included in this analysis. Figure 4.16 shows the heatmap for the classification 
scores for all cell lines, arranged in increasing order of classification score with ovary ttGRN.  
Figure 4.16 – Tissue specificity of endometrial cancer cell lines 
As can be seen, the cell line showing highest similarity and least non-specificity is 
MFE-280, which had been isolated in 199792 but only been cited in literature less than 10 
times. More than 60% of these cell lines have a 25% or above probability of classifying as an 
ovarian cancer, which is not surprising considering the similarity in tissue composition and 
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molecular players between the ovary and the endometrium. The ovarian tumor dataset 
comprised of ~20% of tumors that were of endometroid origin93 and this could also have led 
to the similarity of classification seen by endometrial cancer cell lines to ovarian tumors.   
 Some cell lines show a minor classification with kidney but the probability score is less 
than 0.2 and is not considerably significant. Zhou et al, in 2007, had published a 
comprehensive study researching the properties of 16 endometrial cancer cell lines94, some of 
which overlap with our study, but they do not compare the cell lines to the primary tumor to 
ascertain molecular and phenotypic similarities. The study however, catalogs properties of 
these cell lines such as proliferation rate, morphology, hormone receptor expression, 
tumorigenicity etc. in detail.  
 The cell line showing faint breast classification, RL95-2, was analyzed for the 
expression of Estrogen Receptor (ER) but all endometrial cancer cell lines showed a uniform 
expression of ER. The expression of the ten breast cancer associated TFs95, namely, SOX10, 
NFATC2, ZNF354C, ARID3A, BRCA1, FOXO3, GATA3, ZEB1, HOXA5 and EGR1, was 
looked into next and all of them, except for GATA3 were found to be near basal levels. 
GATA3, however, showed a three-fold and this could have resulted in breast-like 
classification. MFE-296, which is one of the cell lines that shows negligible classification as 
primary endometrial cancer even though it was originally obtained from differentiated human 
endometrial adenocarcinoma. This is one of the few endometrial cancer cell lines to show 
tetraploidy96. In-vivo analysis of tetraploid endometrial tumors reveal that they are similar to 
diploid tumors, but the poor classification of this cell line with our primary tumor data set 
shows that further analysis needs to be conducted into understanding the mechanisms in 
which ploidy affects cancer characteristics in the endometrium.  
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4.3.3 Bone cancer derived cell lines 
Primary bone cancers are a subtype of a group of cancers called sarcomas, which 
broadly refers to the cancers that start in the bone, muscle, connective tissue, fat or blood 
vessels97. Bone cancers are of many different types and the cell lines we have in our query 
dataset belong to 4 distinct types – Ewings sarcoma, osteosarcoma, chondrosarcoma and giant 
cell tumors of the bone. The most common among these, osteosarcoma, is characterized by 
the production of calcified bone (osteoid) by malignant cells, in an aberrant fashion, leading 
to carcinogenesis. Chrondrosarcoma is a cancer of the cartilage tissue while Ewings sarcoma 
occurs in soft tissue. Since osteosarcoma affects children and young adults, a lot of attention 
has been paid to this tumor type, by researchers worldwide98.  
Figure 4.17 – Tissue specificity of bone-derived cancer cell lines 
Analyzing the bone cancer derived cell lines as a part of this study resulted in a very 
non-specific heat up as shown in Figure 4.17. The tissue composition and the genetic networks 
involved in bone cancer formation are starkly different as compared to other tissues, that are 
a part of the training data. In the heat map, there is low background for almost all cell lines 
that shows poor classification. Without a bone cancer training dataset, it becomes difficult to 
analyze the fidelity of osteosarcoma cell lines, and this issue is addressed in section 4.4.  
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4.3.4 Conclusions from this section  
 The intended advantage of a tool like Cancer CellNet is the ability to classify an 
unknown sample into a known tumor type. When querying Cancer CellNet with cell lines 
derived from tumors that are not a part of the training dataset, one of two things can happen. 
If the query data resembles one or more of the training tumor types to a reasonable degree, 
like the similarity between endometrium and ovary, they classify as that tumor type. However, 
while querying a completely unrelated tumor type like bone, with these classifiers, the resulting 
heatmap shows poor classification scores with all tumors and becomes hard to interpret, thus 
requiring CellNet to be retrained including necessary tumor type controls. This calls for the 
need to ensure maximum diversity within the training dataset, so characterization of unknown 
samples becomes possible.  
4.4 Re-training CellNet with osteosarcoma tumor samples 
 In order to be able to analyze the osteosarcoma derived cell lines mentioned above, 
CellNet was retrained with all of the primary tumor samples listed in Table 3.1, and 48 
osteosarcoma primary tumor expression datasets. This allowed the construction of bone 
tumor type ttGRN based classifiers and re-construction of the same for the other tissue types. 
We also made the GRNs larger, allowing more candidate TFs to be a part of each ttGRN in 
order to construct a more comprehensive classifier, which will be used for further analysis.  
 As described in section 4.1, prior to using ttGRN based classifiers generated by 
CellNet, it becomes crucial to ensure that the classifiers are specific and are capable of 
classifying query data satisfactorily. This is done by the “split and assess” method, described 
above. The results of this analysis are shown in Figures 4.18 and 4.19 below.  
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Figure 4.18 – Classification scores to test the quality of the new training classifiers  
Figure 4.19 – Precision-Recall curves for the new CellNet generated classifiers  
Although the classifiers are successful in classifying the tumor data in accordance with 
their tumor type of origin, there appears to be some background classification for tumor types 
*&!
like kidney, pancreas, melanoma and ovary and most of this non-specific background is 
appearing to be with breast or liver tumor type classifier. The PR curves are assessed to better 
understand the sensitivity and precision of these classifiers to accurately predict the tumor type 
of origin for query data.  
Similar to Figure 4.2, ovary and prostate show a less-than-perfect PR curve, but the 
precision is high with a sensitivity of about 0.9, thus making the classifiers a good standard. 
The bone classifier performs a little poorer in comparison, but that may be due to the relatively 
smaller number of samples that constitute the training data set. With these classifiers, the 
osteosarcoma cell lines were re-analyzed and the results are shown in Figure 4.20, where the 
cell lines are arranged in increasing probability to classify as bone tumor type.  
Figure 4.20 – Tissue specificity of bone-derived cancer cell lines using new classifiers 
A study by Mohseny et al in 2011 characterized the in-vitro differentiation and in vivo 
tumorigenic potential for 19 osteosarcoma cell lines, out of which only 5 overlap with our 
study99. They identify 8 cell lines which have the ability to form tumors in immuno-
compromised mice, one of which (HOS143B) was identified as a highly metastatic tumor-
forming cell line. However, the tumors formed were not analyzed with respect to traditional 
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osteosarcoma expression profiles, to ensure that the tumor formed recapitulates the features 
of the cancer that the cell lines were derived from. The cell lines that were ranked by this study 
to be good representatives for OS, based on these two experiments, were among those that 
classified as poor models in our study. U2OS, which is one of the oldest human cell lines 
established is also having low/poor classification to primary tumor data. These differences 
between quantitative and qualitative analysis of fidelity of cell lines show the need for more 
stringent characterization techniques, and we believe that Cancer CellNet is a step in that 
direction.  
4.5 Identification of the unknown origins of certain cancers  
 “Cell of origin” are those cells that receive the first genetic hit or hits, that contributes 
to the initiation and in some cases, the propagation of the cancer100. There are certain cancers 
where these cells of origins are not identified and using Cancer CellNet, we aim to identify the 
possible cells from which these cancers could arise from.  
4.5.1 Tissue origins of cancers with unknown primary tumors 
 The region or tissue of the body where cancer originates is called the primary site and 
that tumor is called the primary tumor. Sometimes, this tumor metastasizes into other organs 
and these are called secondary tumors101. Secondary tumors exhibit characteristics of the 
tissue where the primary cancer originated and are hence, named after that tumor.  However, 
around 2 - 5% of all patients have metastatic tumors where the primary site for the tumor 
remains unknown and these cancers are called Cancers with Unknown Primaries (CUP)102. 
This usually occurs if either the primary tumor is too small to be identified and/or if the 
primary tumor regresses after metastasis and hence, is unidentifiable. Although the metastasis 
for CUP can be found in any part of the body, the most common tissues are lymph nodes, 
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liver, lungs and skin103. There are four major types of CUPs based on the cells present in the 
metastatic tumor – adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and 
poorly differentiated tumors, among which adenocarcinomas comprise of 60% of all 
diagnosed CUPs104.    
With advances in molecular imaging and genomics, there have been significant 
progress made in identifying the mechanisms by which the secondary tumor keeps the 
characteristics of the primary tumor obscure. However, with Cancer CellNet, the GRN status 
of these secondary tumors can be quantified and compared across our training tumor types to 
obtain similarity measures. The study by Kurahashi et al in 2013 generated microarray 
expression profiles for 60 such CUP cancers obtained from patients105 and we use this data 
set as a query into Cancer CellNet. The results are depicted in Figure 4.21.  
Figure 4.21 – Classification score heatmap – Cancers of Unknown Primary samples 
This dataset was collated by isolating CUPs from the lymph nodes or ascites fluid of 
60 patients and their expression profile was obtained. As can be seen from the figure, around 
20% of the samples show maximum similarity to classify as a lung tumor, while 10% classify 
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as ovarian. Interestingly, CUP from patient 35 showed higher than 70% classification with 
both lung and liver, which do not share a lot of functional, phenotypic or GRN similarity.  
A representation of the tumor types the CUP samples classified as and their relative 
distribution, is shown in Figure 4.22. There seem to be some tissues, like melanoma, prostate 
and brain, which have no specific and very minimal non-specific classification. This 
information will be useful for clinicians to direct them to look at tissues like lung, which have 
a higher probability of having had the primary tumor, which may/may not be visible.   
 
Figure 4.22 – Putative tissues of origin of CUP samples 
Although Cancer CellNet classifiers are able to discern the putative origin for a 
majority of the samples profiled based GRN similarity with the ttGRNs, around ~15% of 
these samples still remain non-specific with respect of primary tumor origin. However, 
inclusion of additional primary tumor datasets to train CellNet, like thyroid, gastrointestinal 
system etc. may help provide additional tumor profiles to compare against.  
We propose the possible use of this platform as a diagnostic tool for cases where the 
primary cancer sites are unidentifiable or or is unclear, as it provides a quick and quantitative 
understanding of the tumor profile and can direct the treatment methodologies in those cases. 
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4.5.2 Analyzing the origins of Merkel Cell Carcinomas 
Merkel Cell Carcinoma (MCC) is a highly aggressive form of skin cancer and in 
approximately 80% of the cases is caused by Merkel cell polyomavirus (MCV). It is also called 
neuroendocrine carcinoma of the skin and predominantly occurs among older people, due to 
prolonged sun exposure or a weakened immune system106. A recently discovered virus called 
Merkel Cell Polyomavirus (MCV) is shown to contribute to the development of MCC107 but 
the cells where the disease originates is still unknown and is an area of active research.  
Long term resident cells or epidermal stem cells, as they are popularly called, are 
present in the inter-follicular epidermis and are the cells of origin for MCC in mice108. The 
figure below, adapted from Tilling et al shows the potential cells of origin for MCC in humans, 
and their putative mechanisms for carcinogenesis into MCC16.  
Figure 4.23 – Putative cells of origin and paths to the formation of MCC  
In order to understand the tumor type similarity between MCC and the primary tumor 
types in our training data set, the data obtained by Harms et al (GEO - GSE39612) was used 
as the query dataset to run through Cancer CellNet109. The results are shown in Figure 4.24. 
Since the primary dataset does not include a neuroendocrine tumor profile, most of the MCC 
samples align with brain with scores ranging from 20% to 45%. Tumor profiles between 
*+!
metastatic tumors and primary tumors do not show any significant differences with respect to 
classification scores. Dermal stem cells, which are considered one of the cell types that is 
thought to lead to the formation of MCC, are known players in the formation of melanoma. 
A very small subset of the patient samples shows a classification as melanoma, and all except 
one among those, have a significant probability score. Interestingly, this sample did not classify 
as brain, exhibiting one of the lowest score among these samples.  
Figure 4.24 – Classification score heatmap – Merkel Cell Carcinoma samples   
MCV is a known contributor for the propagation of the MCC and the MCV status of 
these samples was probed into. 13 of the samples had tested positive for the viral status, as 
determined by PCR for the viral gene. Although the number of metastatic tumors included in 
this study are only 4, all of them tested negative for the viral genes and this correlation is yet 
to be explored. MCV is also known to infect stem cells, and Merkel cells, which were originally 
considered a frontrunner as the cell of origin, have been shown to not exhibit the presence of 
this virus due to its post-mitotic nature.  
The results obtained from Cancer CellNet may be the quantitative tool the field lacked 
to analyze the tumor profile of MCCs and with the appropriate tumor classifiers and larger 
number of patient samples, the tumor type similarity for MCC can be identified.  
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Chapter 5 - Discussion 
5.1 Conclusions 
 Using Cancer CellNet as a tool, the cell lines from ten different tumor types were 
analyzed and ideal in vitro models were proposed based on the classification scores. While 
querying cell lines derived from tumors that are not a part of the training data, CellNet is able 
to predict the closest tumor type as the tissue or origin. When none of the classifiers resembles 
the query data, poor classification scores are encountered against all tumor types and in these 
cases, Cancer CellNet needs to be retrained with appropriate primary tumor expression data.  
 The results obtained from this project demonstrate the use of Cancer CellNet platform 
as a diagnostic tool in the clinical setting. While querying clinical samples obtained from 
patients, where the cell origins of the cancer is unknown, based on the classification score with 
the ttGRNs, we can identify the putative tumors of origin to a reasonable degree. As cancer is 
a heterogeneous disease, oftentimes there is a chance for a misdiagnosis while using qualitative 
assays but since Cancer CellNet is a quantitative tool and the results shown above prove 
minimal overlap with other tissues, accuracy of diagnosis can be significantly improved. Since 
microarrays are quite inexpensive and obtaining expression data from samples is faster than a 
majority of clinical assays, using Cancer CellNet in a diagnostic setting to accurately predict 
the cancer profile has tremendous market potential.  
5.2 Limitations of the study 
 Although the advantages of Cancer CellNet are many, we acknowledge that our study 
has a number of limitations. These are listed below:  
1. The extent of diversity in the training data is limited and in order to be able to 
successfully handle samples from any kind of cancer, other tumor types like GI, 
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cervical, thyroid, and individual types of blood cancers like lymphomas, myelomas etc. 
need to be added. Improving the specificity of the classifiers will vastly increase the 
diagnostic value of CellNet in screening samples and identifying tumor type.  
2. In this study, one dataset per cell line was used to determine the fidelity. However, in 
order to predict efficient in-vitro models for cancer with high confidence, more 
replicates per cell line need to be incorporated and the analysis repeated.  
3. Cancer being a heterogeneous disease, has multiple cells that are involved in the 
diseased tissue and sometimes, also contribute to the disease initiation and 
progression. Performing microarray on clinical samples may be an effective way to 
identify an overall cancer profile but in order to use Cancer CellNet as a tool for 
investigating the cell types of origin, it becomes more efficient to use expression data 
from single cells as opposed to a collection of cells. In this respect, modifying Cancer 
CellNet to be able to analyze single cell RNA-sequencing data, which provides the 
maximum resolution into the transcriptional state of a cell presently, will make more 
leeway into understanding the cell origins of cancer.  
4. The number of tumor samples used per tumor type varies, but since CellNet uses a 
modified CLR algorithm in its GRN construction, a minimum of 60 samples per 
tumor type is required to construct a classifier with accurate ttGRN profiles. When it 
comes to using CCN for rare tumor types, obtaining this data set might be challenging.  
5.3 Future directions 
 Adapting Cancer CellNet with additional primary tumor types and querying them 
against multiple datasets obtained from the model cell lines predicted by this study, will enable 
us to predict cell line models for primary tumors with higher accuracy and we intend to do 
this with microarray and RNA-seq data to obtain a better resolution into cancer heterogeneity.  
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Appendix – Cancer CellNet code 
#Cancer CellNet code - training and query  
#Load all required files in S3  
 
#ssh into the instance!!!  
#configure your instance 
aws configure 
 
#create a folder in the ephemeral drive to accommodate the multiple files 
sudo mkdir /media/ephemeral0/data 
sudo chown ec2-user /media/ephemeral0/data 
cd /media/ephemeral0/data 
 
#copy the following files from S3 into the instance 
#contains function definitions 
aws s3 cp s3://cahanlab/pavithra.kumar/code/cellnetr_utils.R ./  
aws s3 cp s3://cahanlab/patrick.cahan/projects/cancer.cellnet/stCancer_Sep_16_2016.R ./ 
#Training sample table 
aws s3 cp s3://cahanlab/pavithra.kumar/code/CCLE_CellLines.csv ./  




















sampTab <- read.csv("stCancer_Sep_16_2016.R") #load the training sample table 
sids <- unique(as.vector(sampTab$exp_id)) 
row.names(sampTab) <- sampTab$sample_id 
 
#Function definitons: 
#1. Fetching files from S3, in parallel 
s3_get_par <- function (bucket, path, fnames){ 
  tfname <- 'tmpfile.txt'; 
  write.table(fnames,tfname, col.names=FALSE, row.names=FALSE, quote=FALSE); 
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  cmd <- paste("cat ", tfname, " | parallel aws s3 cp s3://", bucket, "/", path, "/{} ./", 
sep='');        
  system(cmd); 
} 
 
#2. gzip the files 
utils_unpack<-function (fname){ 
  cmd<-paste("gzip -d ", fname, sep=''); 
  system(cmd); 
  fname<-strsplit(fname, ".gz")[[1]][1]; 
} 
 
#3. Save the files in S3  
s3_put<-function(dir, target, bucket="pcahanrnaseq"){ 
  fpath<-paste(bucket, "/",dir,sep=''); 
  cmd<-paste("aws s3 cp ",target," s3://", bucket, "/", dir, "/", sep=''); 
  cat(cmd,"\n"); 
  system(cmd);   
} 
 
#4. GRN construction  
cn_make_grn <- function (sampTab, expDat, species = "Mm", tfs = NA, grnSampSize = 0,  
    normDat = FALSE, corrs = NA, zscores = NA, cval = 0.5, cvalGK = 0.75,  
    dLevel = "description1", dLevelGK = "description6", zThresh = 4,  
    holmSpec = 1e-06) { 
    targetGenes <- rownames(expDat) 
    if (is.na(tfs)) { 
        cat("Defining transcriptional regulators...\n") 
        tfs <- find_tfs(species) 
    } 
    tfs <- intersect(targetGenes, tfs) 
    if (grnSampSize == 0) { 
        grnSampSize <- min(table(sampTab[, dLevel])) 
    } 
    stGRN <- sample_profiles_grn(sampTab, minNum = grnSampSize) 
    cat("Number of samples per CT: ", mean(table(stGRN[, dLevel])),  
        "\n") 
    expGRN <- expDat[, rownames(stGRN)] 
    if (normDat) { 
        cat("Normalizing expression data...\n") 
        expGRN <- Norm_quantNorm(expGRN) 
    } 
    if (is.na(corrs)) { 
        cat("Calculating correlation...\n") 
        corrs <- grn_corr_round(expGRN) 
    } 
    if (is.na(zscores)) { 
        cat("Calculating context dependent zscores...\n") 
        zscores <- grn_zscores(corrs, tfs) 
    } 
    grnall <- cn_getRawGRN(zscores, corrs, targetGenes, zThresh = zThresh) 
    specGenes <- cn_specGenesAll(expGRN, stGRN, holm = holmSpec,  
	 78	
        cval = cval, cvalGK = cvalGK, dLevel = dLevel, dLevelGK = dLevelGK) 
    ctGRNs <- cn_specGRNs(grnall, specGenes) 
    list(overallGRN = grnall, specGenes = specGenes, ctGRNs = ctGRNs,  
        grnSamples = rownames(stGRN)) 
} 
 
#5. Heatmap - color annotations - definition 
newHm <- function 
### heatmap of the classification result 
(cnRes,  
 ### cellnet result 
 isBig=FALSE 
 ### is this a big heatmap 
){ 
  classMat<-cnRes$classRes 
  ## SORT BY TISSUE TYPE 
  classMat = classMat[,order(colnames(classMat))] 
   
  ## map color to tissue type 
  columns = unique(colnames(classMat)) 
  counts = list() 
  for(i in 1:length(columns)) { 
    counts[[i]] = length(which(colnames(classMat) == columns[[i]])) 
  } 
  annotation_col = data.frame(TissueType = factor(rep(columns, counts))) 
  ann_colors = list(c(columns = rainbow(length(columns)))) 
  ##  
  colnames(classMat)  =  rownames(annotation_col) 
   
  cools<-colorRampPalette(c("black", "limegreen", "yellow"))( 100 ) 
  bcol<-'white'; 
  if(isBig){ 
    bcol<-NA; 
  } 
   
  # generate heatmap 
  pheatmap(classMat, 
           col=cools, 
           border_color=bcol, 
           cluster_rows = FALSE, 
           cluster_cols = FALSE, 
           show_colnames = FALSE, 
           annotation_col = annotation_col, 
           annotation_colors = ann_colors) 
   
} 
 
#Begin Pre-processing!  
#Fetch, decompress, and process by experiment id (sid) 
y=1 
mydate <- utils_myDate() 
master_expQuery <- data.frame() 
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#Looping through samples from each experimental ID to get normalized expression data 
 
for(sid in sids){ 
 stTest<-sampTab[which(sampTab$exp_id==sid), ] 
 
    #downloading raw files from S3 
 for(i in 1:nrow(stTest)){ 
  filename<- stTest$sample_id[i] 
     tmpfname<-paste(filename,".CEL.gz", sep="") 
     s3_get_par("pcahan_cn_cancer", 
"data/human/array/hgu133plus2/raw_data/tumor_CEL_files", tmpfname) 
     stTest$file_name[i] <- paste(stTest$sample_id[i],".CEL",sep="") 
 } 
 
 files <- list.files(pattern = "\\.CEL.gz$") 
 for(ff in files){ 
  utils_unpack(ff)  #unpacking files 
 } 
 




 expQuery<-Norm_cleanPropRaw(stQuery, "hgu133plus2") 
 fname<-paste("expQuery_training_",sid,"_" mydate,".rda", sep='') 
 save(expQuery, file=fname) 
 s3_put("pavithra.kumar/CCN_runs/expQuery", fname, bucket="cahanlab") #save 
the normalized exp matrix in S3 
 
 master_expQuery <- cbind(master_expQuery, expQuery) #bind expQuery for all exp 
ids to get master expQuery table 
 
 #remove .CEL files to free space 
 system(".rm *.CEL") 
 
 #counter  
 print(y) 
 y <- y +1  
} 
 
save(master_expQuery, file = "master_expQuery_training.rda") 
s3_put("pavithra.kumar/CCN_runs/expQuery", 





grnProp<- cn_make_grn(stAll, expAll, species = "Hs", tfs = hsTFs, dLevel = 
"description1",  
 dLevelGK = "description2", normDat=TRUE, cval = 0.5, cvalGK = 0.5)  
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fname<-paste("grnProp","_", mydate,".rda", sep='') 
save(grnProp, file=fname) 
s3_put("pavithra.kumar/CCN_runs", fname,  bucket="cahanlab") 
 
#Split and assess 
 
classifierPerformance <- cn_splitMakeAssess(stAll, expAll, grnProp, prop = 0.5, dLevel = 
"description1",  
 dLevelStudy = "exp_id", dLevelSID = "sample_id") 
fname<-paste("classifierPerformance_new_cnProc","_",mydate,".rda", sep='') 
save(classifierPerformance, file=fname) 
s3_put("pavithra.kumar/CCN_runs", fname,  bucket="cahanlab") 
 




st <- sampTab[order(sampTab$description1),] 
classMat <- cp$classRes 
x <- intersect(rownames(sampTab),colnames(classMat)) 
classMat = classMat[order(rownames(classMat)),x] 
   
cools<-colorRampPalette(c("black", "limegreen", "yellow"))( 100 ) 
bcol<-NA; 
 
fname <- "Classifiers_heatmap.pdf" 
pdf(file = fname) 
pheatmap(classMat, col=cools, border_color=bcol, breaks=seq(from=0, to=1, 
length.out=100), cluster_rows = FALSE, 
           cluster_cols = FALSE, show_colnames = FALSE, fontsize = 10) 
dev.off() 
s3_put("pavithra.kumar/CCN_runs", fname, "_", mydate, bucket="cahanlab") 
 










cnProc<-cn_make_processor(expAll, stAll, grnProp) 
fname <- ("cnProc_",mydate, ".rda",sep='') 
save(cnProc, file=fname) 
s3_put("pavithra.kumar/CCN_runs", fname, bucket="cahanlab") 
 
#Querying CellNet  
 
sampleTab <- read.csv("CCLE_CellLines.csv") 
rownames(sampleTab)<-as.vector(sampleTab$sample_id) 
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sids <- unique(as.vector(sampleTab$description1)) 
cName <- "cell_line" 
y <- 1 
 
for (sid in sids){ 
 stTest<-sampTab[which(sampTab$description1==sid), ]  
   
  for(i in 1:nrow(stTest)){ 
    filename<- stTest$sample_id[i] 
   tmpfname<-paste(filename,".CEL.gz", sep="") 
   s3_get_par("cahanlab", "pavithra.kumar/osteosarcoma_RAW", tmpfname)  
   files <- list.files(pattern = "\\.CEL.gz$")  
 
     for(ff in files){ 
     utils_unpack(ff); 
    } 
   stTest$file_name[i] <- paste(stTest$sample_id[i],".CEL",sep="") 
 }  
   
 write.csv(stTest, file="CCLE_expn.csv") 
   
 stQuery<-expr_readSampTab("CCLE_expn.csv") 
  
 expQuery<-Norm_cleanPropRaw(stQuery, "hgu133plus2") 
   
 fname<-paste("expQuery_osteosarcoma_", mydate,".rda", sep='') 
 save(expQuery, file=fname) 
 s3_put("pavithra.kumar/CCN_runs/expQuery", fname, bucket="cahanlab") 
     
 cnObjName<-(hgu133plus2 = cnProc) 
   
  tmpAns<-cn_apply(expQuery, stQuery, cnProc, dLevelQuery=cName); 
   
 fname<-paste("tmpAns_", sid, mydate,".rda", sep='') 
 save(tmpAns, file=fname) 
 s3_put("pavithra.kumar/CCN_runs/tmpAns", fname, bucket="cahanlab") 
   
  fname<-paste("HeatMap_", sid,"_", mydate,".pdf", sep='') 
  pdf(file=fname, width=40, height=40) 
  newHm(tmpAns, isBig=TRUE) 
  dev.off() 
  s3_put("pavithra.kumar/CCN_runs/Output", fname, bucket="cahanlab") 
   
 system("rm *.CEL") 
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